409
Participants
Start Date
October 31, 2013
Primary Completion Date
June 30, 2014
Study Completion Date
June 30, 2014
Atorvastatin
Administered orally once a day
Evolocumab
Administered by subcutaneous injection
Placebo to Evolocumab
Administered by subcutaneous injection
Research Site, Akita
Research Site, Noda
Research Site, Fukuoka
Research Site, Fukuoka
Research Site, Fukuoka
Research Site, Kitakyusyu-shi
Research Site, Koriyama-shi
Research Site, Koriyama-shi
Research Site, Koriyama-shi
Research Site, Koriyama-shi
Research Site, Koriyama-shi
Research Site, Maebashi
Research Site, Takasaki-shi
Research Site, Sapporo
Research Site, Sapporo
Research Site, Sapporo
Research Site, Tsuchiura-shi
Research Site, Hanamaki-shi
Research Site, Morioka
Research Site, Takamatsu
Research Site, Takamatsu
Research Site, Yokohama
Research Site, Kyoto
Research Site, Sendai
Research Site, Sendai
Research Site, Sendai
Research Site, Tomigusuku-shi
Research Site, Urasoe-shi
Research Site, Ibaraki-shi
Research Site, Osaka
Research Site, Toyonaka-shi
Research Site, Koshigaya-shi
Research Site, Kumagaya-shi
Research Site, Niiza-shi
Research Site, Arakawa-ku
Research Site, Chiyoda-ku
Research Site, Chiyoda-ku
Research Site, Chofu-shi
Research Site, Chuo-ku
Research Site, Edogawa-ku
Research Site, Hachioji-shi
Research Site, Itabashi-ku
Research Site, Katsushika-ku
Research Site, Koto-ku
Research Site, Minato-ku
Research Site, Minato-ku
Research Site, Ōta-ku
Research Site, Setagaya-ku
Research Site, Shibuya-ku
Research Site, Shinagawa-ku
Research Site, Shinagawa-ku
Research Site, Shinagawa-ku
Research Site, Shinagawa-ku
Research Site, Toshima-ku
Lead Sponsor
Amgen
INDUSTRY